MA45672A - Anticorps multispécifiques dirigés contre cd40 et cd137 - Google Patents

Anticorps multispécifiques dirigés contre cd40 et cd137

Info

Publication number
MA45672A
MA45672A MA045672A MA45672A MA45672A MA 45672 A MA45672 A MA 45672A MA 045672 A MA045672 A MA 045672A MA 45672 A MA45672 A MA 45672A MA 45672 A MA45672 A MA 45672A
Authority
MA
Morocco
Prior art keywords
directed against
antibodies directed
multispecific antibodies
multispecific
directed
Prior art date
Application number
MA045672A
Other languages
English (en)
Inventor
Isil Altintas
Friederike Gieseke
Paul Parren
Rik Rademaker
Ugur Sahin
David Satijn
Original Assignee
Biontech Ag
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, Genmab As filed Critical Biontech Ag
Publication of MA45672A publication Critical patent/MA45672A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
MA045672A 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137 MA45672A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016066840 2016-07-14

Publications (1)

Publication Number Publication Date
MA45672A true MA45672A (fr) 2019-05-22

Family

ID=59501399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045672A MA45672A (fr) 2016-07-14 2017-07-14 Anticorps multispécifiques dirigés contre cd40 et cd137

Country Status (14)

Country Link
US (6) US11091557B2 (fr)
EP (1) EP3484922A1 (fr)
JP (2) JP7138630B2 (fr)
KR (2) KR102632202B1 (fr)
CN (2) CN117247458A (fr)
AU (1) AU2017296095B2 (fr)
BR (1) BR112019000512A2 (fr)
CA (1) CA3030636A1 (fr)
EA (1) EA201990293A1 (fr)
IL (1) IL264142A (fr)
MA (1) MA45672A (fr)
MX (1) MX2018015853A (fr)
SG (1) SG11201811431VA (fr)
WO (1) WO2018011421A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3224830A1 (fr) 2015-01-08 2016-07-14 Biontech Ag Agents agonistes se liant aux recepteurs du tnf
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
EP3496536A4 (fr) * 2016-07-20 2020-02-12 IGM Biosciences, Inc. Molécules multimériques fixant cd40 et leurs utilisations
SG11202000198QA (en) * 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CN111511762A (zh) * 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
MX2020002984A (es) * 2017-09-19 2020-07-22 Mab Discovery Gmbh Anticuerpos de cd40 agonistas.
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
WO2020077635A1 (fr) * 2018-10-19 2020-04-23 苏州丁孚靶点生物技术有限公司 Anticorps anti-cd137 et ses applications
JP2022512875A (ja) * 2018-11-06 2022-02-07 ゲンマブ エー／エス 抗体製剤
KR20210095891A (ko) * 2018-11-23 2021-08-03 스트라이크 파마 아베 이중 특이적 접합체
CN110229232B (zh) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
WO2021209017A1 (fr) * 2020-04-17 2021-10-21 苏州丁孚靶点生物技术有限公司 Préparation spécifiquement liée à cd137 et son utilisation
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022036495A1 (fr) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations
CN112321700A (zh) * 2020-09-21 2021-02-05 四川省人民医院 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用
CN114560940B (zh) * 2020-11-27 2023-07-14 缔码生物科技(武汉)有限公司 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用
IL305681A (en) 2021-03-09 2023-11-01 Genmab As Multispecific binding agents against CD40 and CD137 in therapy
WO2023285552A1 (fr) 2021-07-13 2023-01-19 BioNTech SE Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
WO2023174521A1 (fr) 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
TW202409090A (zh) * 2022-05-12 2024-03-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
WO2024059901A1 (fr) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Procédé de sauvetage de cellules immunitaires épuisées
WO2024115725A1 (fr) 2022-12-01 2024-06-06 BioNTech SE Anticorps multispécifique contre cd40 et cd137 en polythérapie avec un anticorps anti-pd1 et une chimiothérapie

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
CA2361421A1 (fr) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU3662101A (en) * 2000-02-01 2001-08-14 Tanox Inc Cd40-binding apc-activating molecules
EP1717251B1 (fr) 2000-10-02 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Anticorps humains anti-CD40 pour le traitement des tumeurs malignes des lymphocytes B
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1487879B1 (fr) 2002-03-01 2012-12-26 Immunomedics, Inc. Mutations ponctuelles dans un anticorps bispecifique, permettant d'augmenter le taux de clairance
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
CA2872136C (fr) 2002-07-18 2017-06-20 Merus B.V. Production par recombinaison de melanges d'anticorps
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
DE602004028272D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
DK1682178T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi af cancere der udtrykker CD-40-antigenet
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1756162A1 (fr) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Agents de couplage recepteurs et leurs applications therapeutiques
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1945260B1 (fr) 2005-11-01 2012-10-24 Novartis AG Utilisations d'anticorps anti-cd40
EP1973576B1 (fr) 2005-11-28 2019-05-15 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CN101821288A (zh) 2007-06-21 2010-09-01 宏观基因有限公司 共价双抗体及其用途
EP2535349A1 (fr) 2007-09-26 2012-12-19 UCB Pharma S.A. Fusions d'anticorps à double spécificité
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2010015792A1 (fr) 2008-08-06 2010-02-11 Argenta Discovery Limited Composés hétérocycliques contenant de l'azote utiles comme modulateurs bifonctionnels des récepteurs m3 et des récepteurs bêta-2
US20110311550A1 (en) * 2008-10-24 2011-12-22 The Scripps Research Institute Agents for hcv treatment
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN106432503B (zh) 2008-12-19 2020-03-06 宏观基因有限公司 共价双抗体及其用途
WO2010111625A1 (fr) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions et procédés permettant d'utiliser des protéines de liaison multispécifiques comprenant une combinaison anticorps-récepteur
EP2424567B1 (fr) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Procédé de fabrication de molécules hétéromultimères
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
EA201890907A1 (ru) 2009-11-30 2020-04-30 Янссен Байотек, Инк. МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
GB201003293D0 (en) * 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
MX353144B (es) 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
EP2569337A1 (fr) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Protéines hétérodimériques et leurs procédés de production et de purification
ES2537207T3 (es) 2010-08-16 2015-06-03 Novimmune S.A. Métodos para la generación de anticuerpos multiespecíficos y multivalentes
JP5753903B2 (ja) 2010-08-24 2015-07-22 ロシュ グリクアート アーゲー 活性化可能な二重特異性抗体
CA2807278A1 (fr) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Anticorps bispecifiques comprenant un fragment fv stabilise par bisulfure
RU2710717C2 (ru) 2010-09-09 2020-01-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1ВВ
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
AU2012328322A1 (en) 2011-10-27 2014-06-12 Genmab A/S Production of heterodimeric proteins
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
DK2914627T3 (da) 2012-10-30 2021-07-12 Apexigen Inc Anti-cd40-antistoffer og fremgangsmåder til anvendelse
CA2892193C (fr) 2012-11-21 2018-06-19 Pharmabcine Inc. Anticorps double cible ciblant la vegfr-2 et la dll4, et composition pharmaceutique comprenant ces deux composantes
SG10201800982QA (en) * 2013-07-05 2018-03-28 Genmab As Humanized or chimeric cd3 antibodies
RS58627B2 (sr) 2014-04-01 2022-06-30 Biontech Cell&Gene Therapies Gmbh Klaudin-6-specifični imuno receptori i t-ćelijski epitopi
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
MA47472A (fr) * 2014-08-12 2019-12-18 Alligator Bioscience Ab Anticorps
CA3224830A1 (fr) * 2015-01-08 2016-07-14 Biontech Ag Agents agonistes se liant aux recepteurs du tnf
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CN107921104A (zh) 2015-02-22 2018-04-17 索伦托治疗有限公司 结合cd137的抗体疗法
MX2017014699A (es) 2015-05-21 2018-04-11 Alligator Bioscience Ab Polipeptidos novedosos.
JP6845846B6 (ja) 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途
EP3356403A2 (fr) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
ES2910365T3 (es) 2016-04-22 2022-05-12 Alligator Bioscience Ab Nuevos polipéptidos biespecíficos contra CD137
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
CA3038020A1 (fr) 2016-09-23 2018-03-29 Merus N.V. Molecules de liaison bispecifique liant cd137
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
WO2018187215A1 (fr) 2017-04-03 2018-10-11 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques à titre d'agoniste de 4-1bb
WO2018213747A1 (fr) 2017-05-19 2018-11-22 Merrimack Pharmaceuticals, Inc. Molécules bispécifiques agonistes de 4-1bb et de cd40

Also Published As

Publication number Publication date
AU2017296095A1 (en) 2019-01-17
US20220064317A1 (en) 2022-03-03
JP2022184871A (ja) 2022-12-13
JP7138630B2 (ja) 2022-09-16
MX2018015853A (es) 2019-08-21
KR20190028508A (ko) 2019-03-18
WO2018011421A1 (fr) 2018-01-18
CN117247458A (zh) 2023-12-19
US11440966B2 (en) 2022-09-13
KR102632202B1 (ko) 2024-02-02
CN109641959B (zh) 2023-08-22
EA201990293A1 (ru) 2019-07-31
US20220033510A1 (en) 2022-02-03
KR20240017129A (ko) 2024-02-06
JP2019533466A (ja) 2019-11-21
US20200062853A1 (en) 2020-02-27
CN109641959A (zh) 2019-04-16
US11939388B2 (en) 2024-03-26
US20230089969A1 (en) 2023-03-23
US20210317225A1 (en) 2021-10-14
US20200247899A1 (en) 2020-08-06
US11084882B2 (en) 2021-08-10
IL264142A (en) 2019-02-28
EP3484922A1 (fr) 2019-05-22
US11091557B2 (en) 2021-08-17
AU2017296095B2 (en) 2024-05-02
BR112019000512A2 (pt) 2019-04-24
SG11201811431VA (en) 2019-01-30
CA3030636A1 (fr) 2018-01-18

Similar Documents

Publication Publication Date Title
MA45672A (fr) Anticorps multispécifiques dirigés contre cd40 et cd137
IL287019A (en) Preparations and methods for internalizing enzymes
MA49823A (fr) Anticorps dirigés contre pd-l1
SG11201707663SA (en) Lyophilization of rna
GB201421083D0 (en) Enzyme inhibitors
GB201421088D0 (en) New enzyme inhibitors
MA50352A (fr) Anticorps multispécifiques
DK3160978T3 (da) Gemcitabin-prodrugs
GB201421085D0 (en) New enzyme inhibitors
EP3280418A4 (fr) Inhibiteurs de btk azacarbazole
EP3302480A4 (fr) Inhibiteurs de la btk
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
EP3268125A4 (fr) Détermination de cellules à l'aide d'amplification
DK3137616T3 (da) Forøgelse af cellulær lipid produktion ved forøgelse af aktiviteten af diacylglycerolacyltransferase og formindskelse af aktiviteten af triacylglycerollipase
MA44067A (fr) Anticorps dirigés contre la quétiapine et utilisation associée
EP3183364A4 (fr) Procédés d'amplification d'arn
DK3371293T3 (da) Fermentering
DK3365107T3 (da) Cellekultur
EP3148971A4 (fr) Inhibiteurs de déubiquitinase
CL2016002961A1 (es) Enzimas de citoquinina sintasa, constructos y métodos relacionados
EP3369434A4 (fr) Inhibiteurs pour enzymes liées à la méthylation hat1 et kat8
DK3224355T3 (da) Enzym-inhibitorkomplekser
FR3023088B1 (fr) Amplificateur audio
EP3128004A4 (fr) Agent enzymatique
DK3390621T3 (da) Forbedret fermentering